SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Jackie Robinson (HR-ML037)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 15judgment calls in the dossier
- 1protocol deviations
- 3orders and referrals without results in the record
- 3evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the urgency of the retina visit, the anti-VEGF and laser sequence, the gradual glucose plan and the timing of dulaglutide after the retina was stable, empagliflozin with lisinopril and the potassium check, the coronary work-up through a pharmacologic stress test, the ankle-brachial index and wound care, and the grief support. |
| provenance review | not_started | | | Sources: SABR, the California legislature, the National Archives, a University of California article, and the Dodgers timeline. The Library of Congress, the National Baseball Hall of Fame, the Jackie Robinson Foundation, the New York Times obituary and Arnold Rampersad's biography could not be read directly. |
| safe messaging review | not_started | | | His son's death is stated once, without its circumstances. Grief is supported as grief; depression screening is synthetic and below the threshold for a safety assessment, and the 988 line is named in the plan. No mental health diagnosis is made. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. He died in 1972, so the rule does not apply. The record still keeps to what the cited sources say about his health and adds no illness they do not report beyond the synthetic modern findings described below.
- Name. The display name is “Jackie Robinson,” which splits simply into a given and family name, so `identity.name_parts` is not used. His legal given names, which the sources print, are not used anywhere in the record, because one of them is a word in other records’ text and the other is part of other figures’ display names; the record has no alias for the same reason. His son is named once, as “Jackie Robinson Jr.,” in the claim about his death. No other figure who has a record is named.
- Living people. His wife and his two younger children are not named; his wife appears only as part of his household. No modern decision, statement or health fact is attributed to any real person; the cardiologist, podiatrist, grief counselor, visiting nurse and retina specialist are fictional or unnamed.
- What could not be verified and was left out. The Library of Congress and Britannica pages were blocked; the National Baseball Hall of Fame, the Jackie Robinson Foundation and the New York Times obituary could not be read directly; Arnold Rampersad’s biography was not available. A 1957 diagnosis year attributed to the Library of Congress appeared only in a search snippet and is not cited; other years given on low-quality sites (1941, 1952) are not used. Claims that he was insulin-dependent while playing, that he had a heart attack in 1968, that both legs would need amputation, his physician’s statements, details of his son’s crash, and his son’s earlier struggles are not used. His appearance at the 1972 World Series is not used.
- Conflicts. Death date: October 24, 1972 (SABR, California legislature, University of California) is preferred; the Dodgers timeline gives October 23. The year of diagnosis is given only as “at 37, about the time he retired” (CLM-0005, certainty probable), with SABR’s note that he acknowledged it a few years after retiring. The leg, stroke and three-heart-attack facts come from one source each and are marked probable where single-sourced.
- What is interpretation. The sources say his near-blindness came from diabetes and its complications but do not name the eye disease; CLM-0009 records diabetic retinopathy as the likely cause, graded R. The earlier heart attacks are not dated, so the modern episode records coronary disease found on a stress test and no prior heart attack, to avoid placing an undated event before the index date.
- Index age and dates. The index visit on July 27, 2026 maps to July 27, 1971, when he was 52: six weeks after his son’s death, two years after the documented leg damage, the year after two mild strokes, and fifteen months before his death. The synthetic date of birth is January 31, 1974 (shift 55 years). Visits on July 29, August 17, August 26, September 21 and October 26, 2026, and the retina, cardiology and laser dates between them, map to the same days of 1971. His home in Stamford comes from the death claim; no source dates his move there, so it is used only in the social history. Past medical history includes only the diagnosis of diabetes (about 1957), the leg damage (by 1969) and the strokes (1970).
- Synthetic clinical picture. Following the presenting-problem pattern, intake records blurred vision with floaters (H53.8), resolved two days later when the retina specialist diagnosed proliferative retinopathy with center-involving macular edema in both eyes (E11.3513) and a right vitreous hemorrhage (H43.11), and exertional chest tightness (R07.89), resolved at the sick visit when the stress test established coronary disease with stable angina (I25.119). Intake text shows only what was known at intake. Diabetes with hyperglycemia, hypertension with albuminuric kidney disease (I12.9, E11.22, N18.2), peripheral artery disease (E11.51), neuropathy (E11.42), the history of strokes (Z86.73), hyperlipidemia and bereavement (Z63.4) are recorded at intake; those with documented anchors are linked to their claims. Every value, image, acuity, thickness, index, score and medicine is synthetic. Height (180 cm) and weights are synthetic. Qualitative results (ECG, fundus and B-scan findings, stress test, PSA, HIV, hepatitis C) appear only in note text.
- Glucose lowering and the retina. The modern plan lowers A1c by about a point every three months (10.4% to 9.2%), starts empagliflozin first, and starts dulaglutide (not semaglutide) at the lowest dose only after the retina specialist judged the proliferative disease controlled, with monthly retina review, as the teaching point on early worsening requires. This is a judgment call: guidelines do not forbid GLP-1 receptor agonists in retinopathy, and the record presents the delay as a shared decision, not a rule.
- Grief and mood. His son’s death (CLM-0011) and his grief (CLM-0012) are marked sensitive. Grief is coded as bereavement (Z63.4), not as a mental disorder. PHQ-9 is 9 at intake and 6 at three months, PHQ-2 is 2, and item 9 is 0, so no safety assessment is required; the 988 line is still named in the plan. Grief counseling at the health center is synthetic.
- Equity. The record treats access and outcomes as part of the plan: a 48-hour retina visit instead of a routine one, low-vision services and accessible diabetes tools, a vascular and foot program that aims to prevent amputation, and shared decisions on prostate screening that name the higher risk in Black men. The University of California article on stress and health disparities is used only for its health facts; no claim is made about the causes of his illness.
- Sick visit. A neuropathic friction blister on the right heel from new shoes (S90.821A), found late because of numb feet and low vision, treated with wound care, offloading, a visiting nurse and podiatry, healed in five weeks. It interacts with his neuropathy, artery disease and vision and does not echo a documented event. The same visit records the cardiology result.
- Preventive visit. A periodic adult preventive visit at 52 (CPT 99396 and 99497 in plain text): colonoscopy chosen, with written medicine instructions for the preparation; PSA after shared decision-making; HIV and hepatitis C once; influenza, PCV20 and zoster dose 1 given, COVID-19 and hepatitis B at the next visit; advance care planning with an unnamed agent.
- Focused visits. The three chronic-care follow-ups (two days with the consultation, four weeks, and three months) are documented as focused visits on the ADA Standards of Care 2026, the AAO Preferred Practice Pattern 2025, the 2024 ACC/AHA PAD guideline, the 2023 chronic coronary disease guideline, KDIGO 2024, IWGDF 2023 and the CMID monographs. One deviation is recorded instead of an invented result: the lipid panel due 4 to 12 weeks after the atorvastatin increase was not ordered at the four-week visit and was drawn at thirteen weeks; no harm (LDL 74 mg/dL), and the next panel, after ezetimibe, was booked before he left. The retina injections, OCT, laser, stress test and wound care are recorded as procedures on their own dates.
- Consultation. The referral and the consultation by Priya Ostrowski-Lane, MD (a fictional retina specialist), two days after intake, are S. The assigned surname was changed to “Ostrowski-Lane” because its second part is a word in another figure’s display name. The consultant answers the six referral questions in line with what the record shows afterwards: proliferative retinopathy with macular edema in both eyes and an attached right retina; monthly aflibercept for three doses (given), laser to the right eye when the blood cleared (done), vitrectomy only if it did not clear (not needed); a gradual A1c fall and a GLP-1 receptor agonist after the retina was stable (dulaglutide at three months, with her agreement); aspirin continued; low-vision services (done) and no driving; and monthly retina visits.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-10-26 Progress note 06 (C-CDA) | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Late: the panel due 4 to 12 weeks after the atorvastatin increase was not ordered at the four-week visit and was drawn today, at thirteen weeks. No harm: LDL 74 mg/dL, total cholesterol 150, HDL 40, triglycerides 180 mg/dL; ALT 30 U/L. Corrective action: follow-up lipids for today's ezetimibe booked before he left, at four to eight weeks |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-07-29 Progress note 02 (C-CDA) | Laboratory | Potassium, creatinine and eGFR | Ordered | Lisinopril increased and empagliflozin started today; check in four weeks |
2026-09-21 Progress note 05 (C-CDA) | Prevention | Colorectal cancer screening | Ordered | Colonoscopy, his choice, with diabetes medicine instructions for the preparation |
2026-09-21 Progress note 05 (C-CDA) | Prevention | Prostate cancer screening | Ordered | PSA after shared decision-making, including the higher risk in Black men |
Evidence to check
Retrospective claims (R)
| Claim | Statement | Certainty |
|---|
| CLM-0009 | His loss of vision was most likely caused by diabetic retinopathy; the sources attribute his near-blindness to diabetes and its complications without naming the eye disease. | probable |
Sensitive claims
| Claim | Grade | Statement |
|---|
| CLM-0011 | D | His eldest son, Jackie Robinson Jr., was killed in an automobile accident on June 17, 1971, at 24. |
| CLM-0012 | D | In his last year he grieved the deaths of his mentor, his mother and his first son. |
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-07-27 | Hemoglobin A1c | 10.4% (high) | High |
| 2026-07-27 | Glucose (random) | 248 mg/dL (high) | High |
| 2026-07-27 | eGFR (CKD-EPI 2021, race-free) | 79 mL/min/1.73 m² (low) | Low |
| 2026-07-27 | Urine albumin-to-creatinine ratio | 86 mg/g (high) | High |
| 2026-07-27 | Total cholesterol | 226 mg/dL (high) | High |
| 2026-07-27 | LDL cholesterol | 142 mg/dL (high) | High |
| 2026-07-27 | HDL cholesterol | 38 mg/dL (low) | Low |
| 2026-07-27 | Triglycerides | 230 mg/dL (high) | High |
| 2026-07-29 | Best-corrected visual acuity, right eye (ETDRS letters) | 35 (low) | Low |
| 2026-07-29 | Best-corrected visual acuity, left eye (ETDRS letters) | 56 (low) | Low |
| 2026-07-29 | Central subfield thickness by OCT, right eye | 412 um (high) | High |
| 2026-07-29 | Central subfield thickness by OCT, left eye | 468 um (high) | High |
| 2026-08-26 | eGFR (CKD-EPI 2021, race-free) | 71 mL/min/1.73 m² (low) | Low |
| 2026-08-26 | Ankle-brachial index, right | 0.68 (low) | Low |
| 2026-08-26 | Ankle-brachial index, left | 0.74 (low) | Low |
| 2026-10-26 | Hemoglobin A1c | 9.2% (high) | High |
| 2026-10-26 | Urine albumin-to-creatinine ratio | 54 mg/g (high) | High |
| 2026-10-26 | eGFR (CKD-EPI 2021, race-free) | 74 mL/min/1.73 m² (low) | Low |
| 2026-10-26 | Triglycerides | 180 mg/dL (high) | High |